Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Neurology
Biotech
AstraZeneca drops MASH drug over disappointing data
AstraZeneca has ended work on one of its drugs for fatty liver disease after viewing disappointing data from a phase 2 study.
James Waldron
Nov 6, 2025 5:21am
Lilly saves gene therapy biotech with $18M upfront deal
Apr 3, 2025 6:00pm
Clario acquires WCG's neuro-focused eCOA business
Mar 12, 2025 3:40pm
Takeda fronts $46M for 2nd small molecule collab with BridGene
Feb 25, 2025 8:00am
Lilly's next focus: Testing incretins in neuro, immunology fields
Feb 6, 2025 2:35pm
Biogen shrinks research team, prioritizes external innovation
Jan 22, 2025 4:10pm
